MedTrace Logo

Individualisation of Voriconazole Antifungal Therapy Antifungal Therapy

NCT01887457 · Status: SUSPENDED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2015-10-07

No results posted yet for this study

Summary

This is a trial to determine whether giving a patient a tailored dose of voriconazole is safe and effective.

Conditions

  • Immunocompromised Patient
  • Aspergillosis
  • Fusarium

Interventions

DRUG

VFEND

voriconazole will be administered in iv form

Sponsors & Collaborators

  • The Christie NHS Foundation Trust

    collaborator OTHER

  • Brynn Chappell

    lead OTHER

Principal Investigators

  • William Hope · University of Liverpool

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2016-11-30
Completion
2016-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01887457 on ClinicalTrials.gov